Protein-engineered hydrogels enhance the survival of induced pluripotent stem cell-derived endothelial cells for treatment of peripheral arterial disease†,Biomaterials Science

当前位置： X-MOL 学术 › Biomater. Sci. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Protein-engineered hydrogels enhance the survival of induced pluripotent stem cell-derived endothelial cells for treatment of peripheral arterial disease†
Biomaterials Science ( IF 5.8 ) Pub Date : 2018-01-25 00:00:00 , DOI: 10.1039/c7bm00883j
Abbygail A Foster ₁ , Ruby E Dewi , Lei Cai , Luqia Hou , Zachary Strassberg , Cynthia A Alcazar , Sarah C Heilshorn , Ngan F Huang

Affiliation

A key feature of peripheral arterial disease (PAD) is damage to endothelial cells (ECs), resulting in lower limb pain and restricted blood flow. Recent preclinical studies demonstrate that the transplantation of ECs via direct injection into the affected limb can result in significantly improved blood circulation. Unfortunately, the clinical application of this therapy has been limited by low cell viability and poor cell function. To address these limitations we have developed an injectable, recombinant hydrogel, termed SHIELD (Shear-thinning Hydrogel for Injectable Encapsulation and Long-term Delivery) for cell transplantation. SHIELD provides mechanical protection from cell membrane damage during syringe flow. Additionally, secondary in situ crosslinking provides a reinforcing network to improve cell retention, thereby augmenting the therapeutic benefit of cell therapy. In this study, we demonstrate the improved acute viability of human induced pluripotent stem cell-derived endothelial cells (iPSC-ECs) following syringe injection delivery in SHIELD, compared to saline. Using a murine hind limb ischemia model of PAD, we demonstrate enhanced iPSC-EC retention in vivo and improved neovascularization of the ischemic limb based on arteriogenesis following transplantation of iPSC-ECs delivered in SHIELD.

中文翻译：

蛋白质工程水凝胶可提高诱导多能干细胞衍生内皮细胞的存活率，用于治疗外周动脉疾病†

外周动脉疾病 (PAD) 的一个关键特征是内皮细胞 (EC) 受损，导致下肢疼痛和血流受限。最近的临床前研究表明，通过直接注射到受影响的肢体来移植 ECs 可以显着改善血液循环。不幸的是，这种疗法的临床应用受到细胞活力低和细胞功能差的限制。为了解决这些限制，我们开发了一种用于细胞移植的可注射重组水凝胶，称为 SHIELD（用于注射封装和长期递送的剪切稀化水凝胶）。 SHIELD 提供机械保护，防止注射器流动期间细胞膜受损。此外，二次原位交联提供了增强网络以改善细胞保留，从而增强细胞疗法的治疗效果。在这项研究中，我们证明了与生理盐水相比，在 SHIELD 中注射注射器输送后，人诱导多能干细胞衍生的内皮细胞 (iPSC-EC) 的急性活力得到改善。使用 PAD 小鼠后肢缺血模型，我们证明了 iPSC-EC在体内的保留增强，并且基于 SHIELD 中输送的 iPSC-EC 移植后的动脉生成改善了缺血肢体的新血管形成。

更新日期：2018-01-25

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11